Implant survivorship analysis after minimally invasive sacroiliac joint fusion using the iFuse Implant System®

Daniel J Cher,1 W Carlton Reckling,2 Robyn A Capobianco1 1Department of Clinical Affairs, SI-BONE, Inc., 2Department of Medical Affairs, SI-BONE, Inc., San Jose, CA, USA Introduction: Surgical revision rate is a key outcome with all permanent implants. The iFuse Implant System® is a permane...

Full description

Saved in:
Bibliographic Details
Main Authors: Cher DJ, Reckling WC, Capobianco RA
Format: article
Language:EN
Published: Dove Medical Press 2015
Subjects:
Online Access:https://doaj.org/article/8d1b9ace4cae4871a03f39d51004c4aa
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Daniel J Cher,1 W Carlton Reckling,2 Robyn A Capobianco1 1Department of Clinical Affairs, SI-BONE, Inc., 2Department of Medical Affairs, SI-BONE, Inc., San Jose, CA, USA Introduction: Surgical revision rate is a key outcome with all permanent implants. The iFuse Implant System® is a permanent implant used to perform minimally invasive sacroiliac joint fusion. The purpose of this study is to determine the surgical revision rate after sacroiliac joint fusion surgery with this system. Methods: Using two internal sources of information, revision surgeries were identified and linked to index surgeries. The likelihood of revision surgery was calculated using the Kaplan–Meier life table approach. Predictors of revision were explored. Results: Four-year survivorship free from implant revision was 96.46%. Revision rate did not differ by sex and was lower for age >65. In all, 24% of revisions occurred within the first 30 days after surgery; 63.5% occurred within year 1. Implant survivorship has improved annually since the device was introduced in 2009. Conclusion: The survivorship rate with this implant is high and improving; the rate is somewhat higher than total hip replacement but lower than that of lumbar spine procedures. Keywords: safety, sacroiliac joint fusion, iFuse Implant System, revision